SCHEMBL3011013

SCHEMBL3011013

COc1ccc(Br)cc1S(=O)(=O)N1CCN(c2nc(-c3ccc(C)cc3)cs2)CC1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.54
KMT2A Q03164 5/20 0.51
USP2 O75604 2/20 0.51
SMN1; SMN2 Q16637 7/20 0.50
ALDH1A1 P00352 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
MAPT P10636 5/20 0.48
MEN1 O00255 4/20 0.48
LMNA P02545 3/20 0.48
MAPK1 P28482 4/20 0.48
POLB P06746 1/20 0.48
RECQL P46063 1/20 0.48
HSD17B10 Q99714 1/20 0.48
RAB9A P51151 5/20 0.48
NPC1 O15118 4/20 0.48
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3649348 0.94 GAA (0.48) GAAKMT2AUSP2SMN1; SMN2ALDH1A1
SCHEMBL3011654 0.93 POLB (0.56) GAAKMT2AUSP2SMN1; SMN2ALDH1A1
SCHEMBL3011599 0.93 GAA (0.54) GAAKMT2AUSP2SMN1; SMN2ALDH1A1
SCHEMBL3002735 0.92 GAA (0.53) GAAKMT2AUSP2SMN1; SMN2ALDH1A1
SCHEMBL3020045 0.91 LMNA (0.59) GAAKMT2AUSP2SMN1; SMN2ALDH1A1
SCHEMBL3013965 0.91 SMN1; SMN2 (0.59) GAAKMT2AUSP2SMN1; SMN2ALDH1A1
SCHEMBL3003103 0.91 GAA (0.52) GAAKMT2AUSP2SMN1; SMN2ALDH1A1
SCHEMBL3009822 0.90 MAPT (0.54) GAAKMT2AUSP2SMN1; SMN2ALDH1A1
SCHEMBL3009150 0.90 GAA (0.51) GAAKMT2AUSP2SMN1; SMN2ALDH1A1
SCHEMBL3016815 0.90 MAPK1 (0.56) GAAKMT2AUSP2SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA GAA 110/4885KMT2A 2680/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.